Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Curing hepatitis C reduces central fatigue, which is weakness originating in the central nervous system.
Twenty-four weeks of Gilead Sciences’ Sovaldi and ribavirin boasted high cure rates among people with genotype 4 of hep C in a recent trial.
The prospect of significantly slowing the spread of hepatitis through treatment has become an exciting prospect as therapy outcomes have...
Interferon, along with depression and fatigue, is an independent variable that dampens the experience of hepatitis C treatment.
AbbVie’s ’3-D’ regimen has had nearly perfect preliminary results in curing people with recurrent geno 1 of hep C post-liver transplant.
Sovaldi treatment has shown good results curing those who have recurring hepatitis C following a liver transplant.
Sovaldi and Olysio cured 94 percent of people who had genotype 1 of hepatitis C and advanced liver disease in a recent trial.
Faldaprevir and deleobuvir plus Presidioâ€™s PPI-668 cured 92 percent of those with genotype 1a of hepatitis C virus when given with riba...
Eight weeks of the fixed-dose combination tablet of Sovaldi and ledipasvir can cure over 90 percent of non-cirrhotic people with genotype 1 of...
In a large trial, AbbVies ’3-D’ combination therapy cured 92 percent to 96 percent of cirrhotic study participants with geno 1 of hep C.
Gilead Sciencesâ€™ fixed-dose combination pill of Sovaldi and ledipasvir cured 94 percent to 99 percent of those with genotype 1 of hepat...
European Union citizens die as a result of viral hepatitis at a rate about 10 times greater than deaths related to HIV.
A fixed-dose combo pill of Sovaldi and ledipasvir is poised to boast a 100 percent success rate in curing hepatitis C among those coinfected w...
The AbbVie ’3-D’ regimen cured 96 percent of people who had genotype 1 of hepatitis C and did not have cirrhosis.
BMS?s daclatasvir and asunaprevir cured between 82 to 90 percent of people with genotype 1b of hepatitis C.
Sovaldi and GS-5816 cured about 95 percent of treatment-naive people with genotypes 1 through 6 of hepatitis C who did not have cirrhosis in a...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.